Related Experiment Video
Updated: Sep 11, 2026
Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome (ARDS)
Published on: April 7, 2021
[Recent developments in the treatment of pediatric acute respiratory distress syndrome]
Insights
Acute respiratory distress syndrome (ARDS) management involves lung-protective mechanical ventilation strategies. New therapies like extracorporeal oxygenation and partial liquid ventilation show promise but require further clinical trials for ARDS patients.
Area of Science:
- Critical Care Medicine
- Pulmonology
- Respiratory Physiology
Background:
- Acute respiratory distress syndrome (ARDS) presents a severe clinical challenge with high mortality rates.
- Conventional mechanical ventilation for ARDS carries risks of iatrogenic lung injury, necessitating advanced therapeutic approaches.
Purpose of the Study:
- To review current and emerging therapeutic principles for managing ARDS.
- To evaluate the effectiveness and limitations of various mechanical ventilation strategies and adjunct therapies in ARDS.
Main Methods:
- Review of existing literature on ARDS pathophysiology and treatment modalities.
- Analysis of mechanical ventilation strategies including positive end-expiratory pressure, high frequency ventilation, and permissive hypercapnia.
- Evaluation of adjunctive therapies such as extracorporeal oxygenation, partial liquid ventilation, inhaled nitric oxide, and exogenous surfactant.
Main Results:
- Lung-protective mechanical ventilation strategies are crucial for minimizing iatrogenic injury.
- High frequency ventilation aids lung recruitment with small tidal volumes.
- Extracorporeal oxygenation is effective but reserved for critically ill patients due to cost and morbidity.
Conclusions:
- Emerging therapies like partial liquid ventilation and inhaled nitric oxide require further investigation.
- Intratracheal exogenous surfactant may offer benefits, but controlled trials are needed.
- Randomized controlled trials with homogenous criteria are essential to define the role of new ARDS treatments.
Abstract:
Acute respiratory distress syndrome (ARDS) is a severe condition with a high mortality rate, despite conventional treatment using mechanical ventilation. Better understanding of the pathophysiology and awareness of important iatrogenic lung injury secondary to mechanical ventilation has led to new therapeutic principles. Mechanical ventilation strategy during ARDS is characterized by positive end-expiratory pressure, increase in the inspiratory time, high inspiratory oxygen concentration and, more recently, use of permissive hypercapnia. High frequency ventilation allows optimal lung recruitment under small tidal volume. The effectiveness of extracorporeal oxygenation techniques is demonstrated, but because of their cost and morbidity these therapies are rational only in patients who seem likely to die. Partial liquid ventilation and inhaled nitric oxide have great potential but require further studies. Intratracheal exogenous surfactant might be beneficial but controlled trials are needed to confirm the usefulness of this expensive therapy. Finally, a number of adjuncts to mechanical ventilation are currently available to minimize iatrogenic lung injury and improve the outcome. The role of these new treatments must be defined with randomized and controlled clinical trials using homogenous inclusion criteria.
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:21Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
01:30Acute Respiratory Failure-III
01:23Acute Respiratory Failure-IV
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:29Respiratory Syncytial Virus Disease